Skip to content

Study on OsseoSpeed™ TX Narrow Implants in the Upper Jaw in a Chinese Population

An Open, Prospective, Multi-center Study to Evaluate OsseoSpeed™ TX Single Implant 3 mm Diameter in the Anterior Maxilla. A 3-years Follow-up Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01389258
Enrollment
45
Registered
2011-07-08
Start date
2011-06-30
Completion date
2016-08-31
Last updated
2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partially Edentulous Jaw

Brief summary

The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX 3mm diameter implant in a Chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior maxilla up to 3 years after loading. Hypothesis: Early loading of the 3 mm implant is a safe and predictable procedure.

Interventions

OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm

Sponsors

Dentsply Sirona Implants and Consumables
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Provision of informed consent 2. Aged 20-75 years at enrollment 3. History of edentulism in the study area of at least two months 4. Neighboring tooth/teeth to the planned crown(s) must have natural root(s) 5. Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in contact with the planned crowns 6. Deemed by the investigator to have a bone height and width suitable for 3.0 mm diameter study implant 7. Deemed by the investigator as likely to present an initially stable implant situation

Exclusion criteria

1. Unlikely to be able to comply with study procedures, as judged by the investigator 2. Uncontrolled pathologic processes in the oral cavity 3. Known or suspected current malignancy 4. History of radiation therapy in the head and neck region 5. History of chemotherapy within 5 years prior to surgery 6. Systemic or local disease or condition that could compromise post-operative healing and/or osseointegration, as deemed by the investigator 7. Uncontrolled diabetes mellitus 8. Corticosteroids or any other medication that could influence post-operative healing and/or osseointegration 9. Smoking more than 10 cigarettes per day 10. Present alcohol and/or drug abuse 11. Involvement in the planning and conduct of the study (applies to both Astra Tech staff and staff at the study site) 12. Previous enrollment in the present study 13. Simultaneous participation in another clinical study, or participation in a clinical study during the last weeks prior to enrollment

Design outcomes

Primary

MeasureTime frameDescription
Implant SurvivalMeasured at the 3-year follow-up visit after implant loading.Implant survival rate evaluated clinically and radiographically.

Secondary

MeasureTime frameDescription
Marginal Bone Level AlterationMeasured at the 3-year follow-up visit after implant loading.Marginal Bone Level (mm) determined from radiographs and expressed as a difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal Bone Level expressed in millimeters obtained at the 3-year follow-up visit compared to values obtained at delivery of the temporary restoration i.e. loading (baseline).
Condition of the Periimplant Mucosa by Assessment of Probing Pocket Depth (PPD).Measured at implant loading and at the 3-year follow-up visit after loading.Change in pocket depth expressed in millimeters at time of the 3 years follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline). Negative value = increased pocket depth.
Implant StabilityMeasured at the 3-year follow-up visit after implant loading.Implant stability evaluated clinically/manually (recorded as stable yes/no).
Presence of PlaqueMeasured at the 3-year follow-up visit after implant loading.Occurence of plaque around the study implant. Presented as proportion of implants that show presence of plaque at time of the 3-year follow-up visit.
Gingival Zenith ScoreMeasured at implant loading and at the 3-year follow-up visit after loading.Gingival zenith score measured from the gingival zenith to the incisal edge of the prosthetic crown with a periodontal probe to nearest 0.5 mm. Presented as change from loading of permanent restoration to time of the 3-year follow-up visit.
Condition of the Periimplant Mucosa by Assessment of Bleeding on Probing (BoP).Measured at implant loading and at the 3-year follow-up visit after loading.Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as % of implants that show presence of bleeding on probing at time of the 3-year follow-up visit.

Countries

China

Participant flow

Participants by arm

ArmCount
OsseoSpeed™ TX
OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
45
Total45

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up5

Baseline characteristics

CharacteristicOsseoSpeed™ TX
Age, Continuous36.4 years
STANDARD_DEVIATION 14.5
Region of Enrollment
China
45 participants
Sex: Female, Male
Female
24 Participants
Sex: Female, Male
Male
21 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 45
serious
Total, serious adverse events
0 / 45

Outcome results

Primary

Implant Survival

Implant survival rate evaluated clinically and radiographically.

Time frame: Measured at the 3-year follow-up visit after implant loading.

Population: Intention to treat (ITT), including all participants that received at least one implant, a total of 45 subjects (47 implants).~A total of 5 subjects (5 implants) had been lost to follow-up at time of the 3-year follow-up visit, giving an overall number of 40 subjects (42 implants) as basis for the analysis of three year survival rate.

ArmMeasureValue (COUNT_OF_UNITS)
OsseoSpeed™ TXImplant Survival42 Implants
Secondary

Condition of the Periimplant Mucosa by Assessment of Bleeding on Probing (BoP).

Condition of the periimplant mucosa by assessment of Bleeding on Probing (BoP). Presented as % of implants that show presence of bleeding on probing at time of the 3-year follow-up visit.

Time frame: Measured at implant loading and at the 3-year follow-up visit after loading.

Population: 40 subjects (42 implants) completed the 3-year follow-up visit. Protocol deviations were excluded (9 subjects, 10 implants), giving a per-protocol analysis population of 31 subjects (32 implants).

ArmMeasureValue (COUNT_OF_UNITS)
OsseoSpeed™ TXCondition of the Periimplant Mucosa by Assessment of Bleeding on Probing (BoP).2 implants
Secondary

Condition of the Periimplant Mucosa by Assessment of Probing Pocket Depth (PPD).

Change in pocket depth expressed in millimeters at time of the 3 years follow-up visit, compared to values obtained at delivery of permanent restoration, i.e. loading (baseline). Negative value = increased pocket depth.

Time frame: Measured at implant loading and at the 3-year follow-up visit after loading.

Population: 40 subjects (42 implants) completed the 3 years follow-up visit. Protocol deviations were excluded (9 subjects, 10 implants), giving a per-protocol analysis population of 31 subjects (32 implants).

ArmMeasureValue (MEAN)Dispersion
OsseoSpeed™ TXCondition of the Periimplant Mucosa by Assessment of Probing Pocket Depth (PPD).-0.26 millimeterStandard Deviation 0.73
Secondary

Gingival Zenith Score

Gingival zenith score measured from the gingival zenith to the incisal edge of the prosthetic crown with a periodontal probe to nearest 0.5 mm. Presented as change from loading of permanent restoration to time of the 3-year follow-up visit.

Time frame: Measured at implant loading and at the 3-year follow-up visit after loading.

Population: 40 subjects (42 implants) completed the 3-year follow-up visit. Protocol deviations were excluded (9 subjects, 10 implants), giving a per-protocol analysis population of 31 subjects (32 implants).

ArmMeasureValue (MEAN)Dispersion
OsseoSpeed™ TXGingival Zenith Score-0.03 millimeterStandard Deviation 0.74
Secondary

Implant Stability

Implant stability evaluated clinically/manually (recorded as stable yes/no).

Time frame: Measured at the 3-year follow-up visit after implant loading.

Population: 40 subjects (42 implants) completed the 3-year follow-up visit. Analysis of implant stability was performed on the All Patients Treated (APT) population.

ArmMeasureValue (COUNT_OF_UNITS)
OsseoSpeed™ TXImplant Stability42 implants
Secondary

Marginal Bone Level Alteration

Marginal Bone Level (mm) determined from radiographs and expressed as a difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal Bone Level expressed in millimeters obtained at the 3-year follow-up visit compared to values obtained at delivery of the temporary restoration i.e. loading (baseline).

Time frame: Measured at the 3-year follow-up visit after implant loading.

Population: 40 subjects (42 implants) completed the 3-year follow-up visit. Protocol deviations were excluded (9 subjects, 10 implants), giving a per-protocol analysis population of 31 subjects (32 implants).

ArmMeasureValue (MEAN)Dispersion
OsseoSpeed™ TXMarginal Bone Level Alteration0.52 millimeterStandard Deviation 0.84
Secondary

Presence of Plaque

Occurence of plaque around the study implant. Presented as proportion of implants that show presence of plaque at time of the 3-year follow-up visit.

Time frame: Measured at the 3-year follow-up visit after implant loading.

Population: 40 subjects (42 implants) completed the 3-year follow-up visit. Protocol deviations were excluded (9 subjects, 10 implants), giving a per-protocol analysis population of 31 subjects (32 implants).

ArmMeasureValue (COUNT_OF_UNITS)
OsseoSpeed™ TXPresence of Plaque2 implants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026